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The autoimmune rheumatic diseases (ARDs) are a heterogeneous group of 
disorders characterized by dysregulation of the immune system leading to tissue 
injury. These conditions present challenges in terms of both diagnosis and 
management. An increased understanding of pathogenesis, newer diagnostic 
markers and the availability of targeted biological treatments has, however, improved 
the outlook for patients. We are delighted to introduce complementary articles written 
by opinion leaders in these conditions covering the diverse spectrum of ARDs that 
physicians are likely to encounter in routine practice, with practical guidance on 
diagnosis and management as well as mention of exciting new developments.  
  
An approach to immunological testing in different clinical circumstances is given by 
Drs Derrett-Smith and Campochiaro, who provide an overview of the role of 
autoantibodies in the diagnosis and monitoring of ARDs, and explain what additional 
supportive diagnostic evidence may be required. It is important to bear in mind that 
overlap syndromes  also exist and variants of the scenarios described  occur.  
  
Distinctions in autoantibody profiles between disease subtypes are well described for 
certain ARDs but increasingly recognized in others. Professor Herrick describes how 
two subtypes of systemic sclerosis (limited cutaneous, diffuse cutaneous) have very 
different natural histories and prognoses, but points out that advances in treatment 
are leading to improved quality of life and increased survival. Drs Clarke and Giles 
mention that increasing evidence implicates non-thrombotic mechanisms in the 
pathogenesis of obstetric antiphospholipid syndrome (OAPS) by antiphospholipid 
antibodies, and that progression to thrombosis in patients with OAPS is scarce 
compared with thrombotic APS, suggesting that OAPS is a distinct subset within 
APS. 
  
Interest in new biological therapies targeting various immune pathways remains 
high, although trials of new agents have not always been successful. In systemic 
lupus erythematosus, Drs Yeo and Dias and Professor Isenberg detail success with 
belimumab but also list various other failed agents. In their overview of vasculitides, 
Drs Kidder, Dospinescu, Karabayas and Basu emphasize the differences and 
similarities between vasculitides, and highlight the risk–benefits of current treatments 
using conventional and biological agents. The diagnostic difficulties and 
management strategies in medium vessel vasculitis are explored by Drs Hewins and 
King[CMW1], while Dr Karangizi and Professor Harper focus on small vessel vasculitis 
and emphasize that rapid diagnosis and treatment is vital to prevent organ damage. 
In ANCA-associated vasculitis, rituximab or cyclophosphamide with high-dose 
corticosteroids is equally effective as induction therapy, providing options for 
treatment individualization. However, relapses remain common, and maintenance 
treatment type and duration must also be tailored to the individual. In their overview 
of large vessel vasculitis, Drs Tracy, Cardy and Carruthers describe an emerging 
role for biological therapies and increasing use of temporal artery ultrasound in 
diagnosis.  
 
Alternative therapeutic options are also being investigated. Professor Herrick 
describes fibrotic and vascular features of systemic sclerosis that can now be 
targeted, while Drs Parker, Lilleker, Roberts and Chinoy explain that non-
inflammatory pathways are being scrutinized as future targets for treatment of 
autoimmune myopathies. Finally, Drs Dumusc and Rao and Professor Bowman 
remind us that better use of symptomatic therapies can still make a big difference to 
patients with Sjögren’s syndrome, while trials of biological therapy are underway. 
 
 
 
  
